BioLineRx announced top line results from the Phase 3 GENESIS trial. A
prior interim analysis indicated that GENESIS easily cleared its primary endpoint,
and new data showed that 70% of patients achieved optimal stem cell yields after
≤2 apheresis sessions compared to 14.3% on G-CSF + placebo (p<0.0001). Per
investigator discretion, 88.3% of patients proceeded to transplant after a single
apheresis session versus roughly 10.8% in the control arm, which could translate to
lower overall costs. Despite the usual caveats associated with cross-trial comparisons,
we believe the GENESIS data suggest motixafortide could be competitive with
plerixafor, which is already approved for use as a stem cell mobilizer. We believe the
positive data could support an NDA filing in 1H22. Reiterate Outperform, $10 PT
Uncategorized
Hearing Oppenheimer Reiterates Outperform Rating And $10 Price Target On BioLineRx
BioLineRx announced top line results from the Phase 3 GENESIS trial. A
prior interim analysis indicated that GENESIS easily cleared its primary endpoint,
and new data showed that 70% of patients achieved optimal
Related Posts
Xi’s The Boss! Chinese President Could Gain Lifetime Rule In Communist Party Meeting
China’s Communist Party has launched a four-day closed-door meeting that could result in President Xi Jinping gaining lifetime leadership powers.
Xos Registration Statement Related to Business Combination With NextGen Acquisition Corporation Declared Effective by SEC
Special meeting of stockholders of NextGen Acquisition Corporation scheduled for August 18, 2021 at 9:00 a.m. Eastern time
Upon closing, Xos will be listed on NASDAQ under the new ticker symbol "XOS"
The
Piper Sandler Downgrades Stock Yards Bancorp to Underweight, Lowers Price Target to $73
Piper Sandler analyst Brendan Nosal downgrades Stock Yards Bancorp (NASDAQ:SYBT) from Neutral to Underweight and lowers the price target from $75 to $73.